eGenesis-Full-color-Logo-with-Tagline-RGB-high-res.png
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
October 26, 2023 08:30 ET | eGenesis
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, will present new data and host a...
eGenesis-Full-color-Logo-with-Tagline-RGB-high-res.png
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
October 11, 2023 11:05 ET | eGenesis
- Proof of concept study resulted in life-supporting organ function and recipient survival of over two years    - Donor kidneys carrying human transgenes resulted in longer survival time CAMBRIDGE,...
eGenesis Logo - Engineering Hope.png
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
June 13, 2023 05:00 ET | eGenesis
CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, today announced the publication of a...
eGenesis
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
June 05, 2023 08:30 ET | eGenesis
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American...
eGenesis Logo - Engineering Hope.png
eGenesis Announces Knut Niss as Chief Technology Officer
January 24, 2023 08:30 ET | eGenesis
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss,...
eGenesis Logo - Engineering Hope.png
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
January 09, 2023 08:30 ET | eGenesis
-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients- ...
eGenesis Logo - Engineering Hope.png
eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
April 19, 2022 08:30 ET | eGenesis
Dr. Curtis succeeds Paul Sekhri, who remains on Board of Directors Reflects company’s focus on advancement of portfolio toward clinical development CAMBRIDGE, Mass., April 19, 2022 (GLOBE...
eGenesis Logo - Engineering Hope.png
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
April 04, 2022 08:30 ET | eGenesis
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of Eliezer...
eGenesis Logo - Engineering Hope.png
eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model
March 09, 2022 08:30 ET | eGenesis
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration...
eGenesis Logo - Engineering Hope.png
eGenesis Appoints Bradford Smith as an Independent Member of Its Board of Directors
June 09, 2021 08:00 ET | eGenesis
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of...